8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Mar 23, 2026·SEC
Intensity Therapeutics, Inc.(INTS)Earnings, Financials & Key Ratios
INTS•NASDAQ
$4.10
Price updated Jun 27, 2026
AboutIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Show more
- Revenue$0
- EBITDA-$12M+26.4%
- Net Income-$12M+28.7%
- EPS (Diluted)-8.56+70.7%
- ROE-156.9%+22.5%
INTS Price & Volume
Intensity Therapeutics, Inc. (INTS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Long-term Capital Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical-stage liquidity constraints
"Intensity Therapeutics remains a high-risk, pre-revenue biotechnology firm heavily reliant on external financing to sustain its INT230-6 clinical development pipeline. While the company maintains a lean asset structure, the consistent operating losses, which reached $2.5 million in 2026Q1, underscore a lack of commercial scale and significant exposure to equity dilution. Investors should monitor the company's ability to reach critical data readouts before its $10.2 million cash balance is exhausted by ongoing R&D expenditures."
Verdict Logic
the company's precarious liquidity profile, evidenced by a $10.2 million cash balance against consistent quarterly operating losses, suggests a high probability of dilutive financing in the near term.
INTS Growth Metrics
Intensity Therapeutics, Inc. (INTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM28.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM73.45%
Return on Capital
10 Years-144.31%
5 Years-179.8%
3 Years-187.87%
Last Year-159.81%
INTS Recent Earnings
Intensity Therapeutics, Inc. (INTS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (36%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.96+19.3%
$1.19
Rev
—
—
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$1.69-36.3%
$1.24
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.06+0.0%
$0.06
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.13-116.7%
$0.06
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.96vs $1.19+19.3% | — |
| Q2 2026 | Mar 27, 2026 | $1.69vs $1.24-36.3% | — |
| Q4 2025 | Nov 6, 2025 | $0.06vs $0.06+0.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.13vs $0.06-116.7% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Intensity Therapeutics, Inc. (INTS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.10 | $103.89M | -0.48 | — | — | -156.9% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $35.26 | $2.35B | -9.04 | -78.63% | -34596.22% | -50.72% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $1.02 | $129.73M | -0.91 | 14.85% | -173.02% | — | — | |
| $30.88 | $1.57B | -58.26 | 20% | -4.88% | -4.83% | — |
Compare INTS vs Peers
Intensity Therapeutics, Inc. (INTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INTS SEC Filings & Documents
Intensity Therapeutics, Inc. (INTS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when INTS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INTS Frequently Asked Questions
Intensity Therapeutics, Inc. (INTS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is INTS profitable?
Intensity Therapeutics, Inc. (INTS) reported a net loss of $10.7M for fiscal year 2025.
Dividend & Returns
What is INTS's return on equity?
Intensity Therapeutics, Inc. (INTS) has a return on equity (ROE) of -156.9%. Negative ROE indicates the company is unprofitable.
What is Intensity Therapeutics, Inc.'s free cash flow?
Intensity Therapeutics, Inc. (INTS) had negative free cash flow of $9.1M in fiscal year 2025, likely due to heavy capital investments.